ReviewBioactive materials2026
Control of immunogenic responses of microorganism-synthesized biopolymers for 3D bioprinting tissue engineering and regenerative medicine.
Review in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiscale bone remodeling in COVID-19: from osteoimmune signaling to structural and mechanical impairment.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Different biopolymers are synthesized by diverse microorganisms through cell and genetic engineering for their applications to organoids, tissue engineering, and regenerative medicine with advanced technologies such as 3D bioprinting, microfluidics, and others. All living bodies repair or replenish their tissues, organs, and systems by synthesizing different biopolymers secreted into their extracellular matrix. Microbially synthesized biopolymers have an advantage over the bulk-synthesized ones due to precise control over the synthesis process, resulting in a tunable molecular structure, molecular weight, and other important properties. This provides an edge over traditional biomaterials as immunomodulatory during tissue engineering. For clinical applications of tissue engineering, the employed biopolymers should be of medical grade with controlled immunogenic responses during and after their implantation, offering precision fabrication of tissue engineering scaffolds and adequate functional tissue regeneration by replacing the scaffolds with their matching biodegradation rates. This review focuses on control of immunogenic responses caused by microorganism-synthesized biopolymers in their applications to 3D bioprinting and other tissue engineering modalities. The synthesis, fermentation, and purification processes of microbial biopolymers and their applications in 3D bioprinted tissue engineering are explained in brief for different exopolysaccharides, proteins, polypeptides, and polyesters. The contents are focused on the preparation of medical-grade polymers, their limited chemical uses, and green and sustainable approaches for the functionalization of polymers and hydrogels in tissue engineering. The immunogenic responses (mostly innate), strategies to control them, and related advantages and concerns are mainly discussed in detail, targeting their successful clinical implementation in the 3D bioprinting-based and other tissue regeneration and reconstruction domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.